Related references
Note: Only part of the references are listed.Regression of a large malignant gastrinoma on treatment with Sandostatin LAR (R): A case report
Dan Granberg et al.
DIGESTION (2008)
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Peptide receptor radionuclide therapy
Flavio Forrer et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Biotherapy
U. Ploeckinger et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma
F Panzuto et al.
ANNALS OF ONCOLOGY (2006)
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors:: A randomized trial
R Arnold et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2005)
Restoration of functional gap junctions through internal ribosorne entry site-dependent synthesis of endogenous Connexins in density-inhibited cancer cells
H Lahlou et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium
RL Adams et al.
BRITISH JOURNAL OF CANCER (2005)
Somatostatin receptor subtype-dependent regulation of nitric oxide release: Involvement of different intracellular pathways
S Arena et al.
MOLECULAR ENDOCRINOLOGY (2005)
High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours
SV Welin et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
K Öberg et al.
ANNALS OF ONCOLOGY (2004)
The diagnosis and medical management of advanced neuroendocrine tumors
GA Kaltsas et al.
ENDOCRINE REVIEWS (2004)
Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells
JW Sall et al.
EXPERIMENTAL EYE RESEARCH (2004)
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors -: The International Lanreotide and Interferon Alfa Study Group
S Faiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities
T Florio et al.
ENDOCRINOLOGY (2003)
Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis
J Guillermet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Opportunities in somatostatin research: Biological, chemical and therapeutic aspects
G Weckbecker et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors
ML Fjallskog et al.
MEDICAL ONCOLOGY (2003)
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
C Bruns et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors -: A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis
M Papotti et al.
VIRCHOWS ARCHIV (2002)
Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies
H Kulaksiz et al.
GUT (2002)
Octreotide therapy for tumor-induced osteomalacia
J Seufert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Growing vascular endothelial cells express somatostatin subtype 2 receptors
JC Watson et al.
BRITISH JOURNAL OF CANCER (2001)
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells
R Mentlein et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro
G Tulipano et al.
NEUROENDOCRINOLOGY (2001)
Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients
S Cascinu et al.
CANCER INVESTIGATION (2001)
Somatostatin receptor subtype expression in human tumors
LJ Hofland et al.
ANNALS OF ONCOLOGY (2001)
Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells
MG Cattaneo et al.
FEBS LETTERS (2000)
Treatment of neuroendocrine GEP tumours with somatostatin analogues - A review
R Arnold et al.
DIGESTION (2000)
Share Paper
